PURIFICATION AND CHARACTERIZATION OF BACTERIOCIN FROM LACTOBACILLUS ACIDOPHILUS HT1 AND ITS APPLICATION IN A CREAM FORMULA FOR THE TREATMENT OF SOME SKIN PATHOGENS

Hiba T. Rasheed, Khalid J. K. Luti, Mouruj A. Alaubidy

ABSTRACT
This study was aimed to purified and characterized the bacteriocin produced from Lactobacillus acidophilus HT1, in order to use it in a skin pharmaceutical formula. The optimal conditions for bacteriocin production was investigated and results showed that modified nutrient broth was the best medium with glucose (30 gm/L) and yeast extract (7 gm/L) with peptone (7 gm/L) were the optimum carbon and nitrogen sources. In addition, 2% inoculum size, 37°C and pH 6.4 were the optimal conditions to obtain maximum bacteriocin of 640 AU/ml after 24 hrs. The bacteriocin was purified using 70% ammonium salt saturation and gel filtration with sephadex G50 that resulted 20% yield and 2560 AU/ml of activity, then the partial purified bacteriocin was characterized and found the bacteriocin was protein in nature and kept its activity after 10 min at 20, 30 and 40°C, however 50% of the activity was lost at 50°C. Moreover, it showed stability at pH 6 and 7 for 30 min whereas; no activity was observed at pH 4 and 9. In addition, results showed that bacteriocin has a bactericidal effect rather than bacteriostatic. A cream formula contains the bacteriocin was prepared which already examined in vitro and in vivo. The effectiveness of the formula was confirmed using Klebsiella sp., Staphylococcus aureus and Pseudomonas aeruginosa as indicator strains. Results established that treatment at the onset time was more effective and the time of healing was decreased.

Key words: skin disease, antibacterial, probiotics.

Received: 2/11/2019, Accepted: 9/2/2020
INTRODUCTION

Among the lactic acid bacteria, Lactobacilli (the species of the genus Lactobacillus) are the most commonly intestinal microbiota of vertebrates, including humans and involve themselves in fermentation of various foods, thereby improving the food quality and the health (10). Such microorganisms are generally recognized as safe (GRAS) and can be used as probiotics (10, 15). The antibacterial activity of probiotic Lactobacilli sp. appears to act through multifunctional ways, particularly by secreting antimicrobial substances such as bacteriocins and counteracting the spread within the colonized body or competing for nutrients and binding sites (9, 16). Bacteriocins are natural antimicrobial peptides produced by bacteria and can inhibit or kill bacterial strains mainly related to the producing bacteria (1,19). Bacteriocins are considered as one of the bacterial weapons due to their specific characteristics with large diversity of function, structure and stability to heat. Many recent studies have identified and purified bacteriocins for different applications ranging from maintaining human health to food technology such as extending food preservation time, cancer therapy and treat pathogen disease (19). The skin and outer tissues are in direct contact with the environment and as a result microbes have easy enter to colonize these areas of the body. Therefore, our skin is populated by billions of numerous bacteria. Naturally, there are many microorganisms associated with skin infections (atopic dermatitis (AD), eczema, acne and burns contaminated) like Propionibacterium acnes, Staphylococcus aureus, Staphylococcus epidermidis, Pseudomonas aeruginosa, Corynebacterium (13). Experimental studies have shown that probiotics can exert specific influences in the dermatology via helping to treat skin conditions including bacterial infections, psoriasis, dermatitis, and the external signs of aging, acne, rosacea and yeast (7). The action of probiotics is mainly based on producing antimicrobial compounds in particular, bacteriocins which can exert their health effects to the skin indirectly through dietary supplementary formulations or directly through cutaneous formulations (7). This study was focused on producing a bacteriocin from local isolate of Lactobacillus acidophilus with an activity against some common skin pathogens in order to introduce it in a pharmaceutical skin formula. The study involved testing the affectivity of the formula in vivo and in vitro.

MATERIALS AND METHODS

Microorganism

A local isolate of Lactobacillus acidophilus HT1 was used throughout this work. This isolate was obtained from dairy products and human mouth samples and already identified through some biochemical tests and cultural characteristics as described by Bergey’s manual and via molecular detection using 16S ribosomal RNA gene (data not shown). Through preliminary tests, this isolate showed an ability to produce an active bacteriocin against several bacteria and hence was chosen to be used in this study. The maintenance of L. acidophilus HT1 was in MRS medium and incubated at 37ºC for 48hrs in microaerophilic conditions.

Optimization of culture conditions

Several optimization experiments were performed in order to determine the medium and culture conditions that support the maximal production of bacteriocin. The experiments involved testing different media including: Modified MRS broth (8) Modified Nutrient broth (NB), MRS broth, Low molecular weight liquid medium (LMWLM), Tryptone Glucose Yeast (TGY) (23), Tryptone soya broth, Nutrient broth and MRS broth (21). In addition, the best and concentration of carbon and nitrogen sources, inoculum size, temperature, pH and incubation time were investigated. Basically, modified nutrient medium contain peptone and yeast extract which were subjected to optimization strategy in order to choose one nitrogen source that support both growth and bacteriocin production by L. acidophilus HT1. The procedure was based mainly on the removal experiment optimization approach as follow: first, each nitrogen source was investigated separately at 7 g/L then half and equally amounts for the two-nitrogen sources amount as shown in Table 1. In all experiments, several 250 ml Erlenmeyer flasks each
Table 1. Optimization of nitrogen source in the modified nutrient medium by the removal experiment optimization approach

| Medium composition | Yeast extract (g/l) | Peptone (g/l) |
|--------------------|---------------------|--------------|
| Control            | 2                   | 5            |
| Medium 1           | 7                   | 0            |
| Medium 2           | 0                   | 7            |
| Medium 3           | 3.5                 | 3.5          |
| Medium 4           | 2.0                 | 2.0          |
| Medium 5           | 1.75                | 1.75         |
| Medium 6           | 7                   | 7            |
| Medium 7           | 2.5                 | 4.5          |
| Medium 8           | 4.5                 | 2.5          |
| Medium 9           | 10                  | 10           |

**Determination of bacteriocin activity**

Well diffusion assay was used to evaluate the production of bacteriocin of isolates as follows: An Amount of 20 ml of MRS broth was inoculated with 2% of an overnight culture of each isolate contained approximately 10⁸ cells/ml. Then, media were incubated for 24 hrs at 37°C. After incubation, the culture broth was centrifuged at 10000 rpm for 15 min and the cell-free supernatant (CFS) was collected and filtered with 0.22μmMillipore filter paper under sterile conditions. Several drops of 1 N NaOH were added until reach pH for neutralize the effect of organic acid and 10μl catalase solution was added to avoid the H₂O₂ activity. Bacteriocin activity was detected using the dilution assay: a twofold dilution series of CFS of each isolate was prepared and bacteriocin activity was determined in each dilution against *Pseudomonas aeruginosa* using agar well diffusion assay (2). The highest dilution producing an inhibition zone (DF) reflected the strength of bacteriocin activity. The bacteriocin activity which is known as arbitrary unites (AU) was determined using the following equation (2):

\[
AU/\text{ml} = \frac{1}{DF} \times \frac{1000}{\text{volumes spotted in } \mu l}
\]

**Purification of bacteriocin**

Bacteriocin was first precipitated by ammonium sulphate at different saturation levels (20, 40, 50, 60, 70, 80, 90)% at 4°C. The precipitate was separated by centrifugation for 30 min at 10000 rpm. Then the precipitates were dissolved in an appropriate volume of phosphate buffer (0.1M, pH 7.2) and dialyzed in 0.5 liter of phosphate buffer overnight at 4°C using dialysis membrane tubes (1 kDa MW cutoff). The buffer was replaced four times. The antibacterial activity of the dialyzed protein was determined by agar well diffusion assay using *P. aeruginosa* as an indicator strain (6). The resulting bacteriocin was loaded on a column (3 x 20 cm) of sephadex G-50 gel filtration. Elution was performed with phosphate buffer (0.1 M, pH 7.2) with a flow rate of 36 ml/hour and fractions of 3 ml. The absorption was measured at 280 nm. The fractions were tested for antibacterial activity against *P. aeruginosa* as an indicator strain by well agar diffusion assay. Fractions showed antimicrobial activity were mixed in one tube and protein concentration with Bradford method (14) and bacteriocin activity were determined (12).

**Characterization of bacteriocin**

The sensitivity of the bacteriocin produced from *Lactobacillus acidophilus HT1* to the proteolytic enzyme trypsin was tested. Trypsin was dissolved in 0.1 M potassium phosphate buffer (pH 7.2) in a test tube contained the bacteriocin solution with an activity of 2560 AU/ml for a final concentration of 1 mg trypsin/ml. The control contained the bacteriocin solution with an activity of 2560 AU/ml without trypsin. Tubes were incubated at 37°C and bacteriocin activity was measured at zero time and after 30 and 90 mins using the well diffusion assay method (5,22). Furthermore, in order to test the thermo stability of bacteriocin, samples were exposed to different temperatures (30, 40, 50, 60, 70, 80, 90) ºC for 10 mins followed by cooling on an ice-bath. The residual activity was then determined by agar-well diffusion technique against indicator strain. In addition, bacteriocin was treated with either 0.1N HCl or 0.1 N NaOH to achieve the desired pH values between 4 and 9. The pH adjusted crude extracts were incubated for 30 mins.
After incubation, aliquots were neutralized and activity was measured by agar-well diffusion technique against indicator strain.

**Mode of bacteriocin action**

The mode of action of the bacteriocin against *P. aeruginosa* was investigated. A volume of 0.5 ml of the partial purified bacteriocin with total activity of 2560 AU/ml was added to 10 ml of an overnight culture of *P. aeruginosa* grown in nutrient broth at 37°C (OD 600 nm =0.6 of *P. aeruginosa*). Control culture was prepared without adding bacteriocin. Changes in the turbidity at 600 nm and viable cells count (cfu/ml) were measured at zero time and after 10, 30, 60, and 120 min of incubation. Viable cells count was determined on nutrient agar plates (20).

**Preparation of pharmaceutical formula including bacteriocin**

A cream contained the partial purified bacteriocin was prepared as follow modified (17): An amount of 0.1 gm of methyl paraben was dissolved in 1ml of ethanol (70%). Then 49 ml of olive oil was gradually added with continues mixing. 5 ml of partially purified bacteriocin with an activity of 2560 AU/ml was added with mixing until homogenization. Next, an amount of 50 gm of white petroleum vaseline was added gradually with continuous mixing to homogenization.

**Preparation of bacterial indicators**

Three multidrug resistant bacterial isolates: *Staphylococcus aureus*, *Klebsiella* sp, *Pseudomonas aeruginosa* were used as indicators in *in vitro* and *in vivo* experiments. These indicators were activated in brain heart infusion broth and incubated at 37°C for 24hrs. The number of cells was adjusted according to McFarland tube (0.5) which is equal to 1.5×10^8 cell/ml at 600nm.

**In vitro evaluation of formula including bacteriocin**

The antibacterial activity within the formula containing bacteriocin as active material was investigated by well diffusion method (18).

**In vivo evaluation of formula including bacteriocin**

Number of 12 local white rabbits were divided into 3 groups each group included 3 animals as treated animals and the fourth one was considered as a control. Each group was specified for one indicator bacteria. After adaptation period (3 days), rabbits’ shoulder and thigh regions were shaved and injured using a scalpel. Then, each rabbit group was infected with one of bacterial indicator and grouped as (1,2 and 3) for *Pseudomonas aeruginosa*, *Staphylococcus aureus* and *Klebsiella* respectively. Each group of experiment was treated as follow: One of rabbit are treated at the onset time after infection (treatment directly after infection), this group was considered as prophylactic group. Another lab. animal was treated with final formula containing active material (bacteriocin) after few hours from infection time and considered as treatment group. The last one was treated after inflammation appearance by using the formula components only without active material (bacteriocin). The experiment time was based on the time of complete healing and this new formula was applied twice daily.

**RESULTS AND DISCUSSION**

The increasing developments of resistance to antibiotics have heightened the need for new strategies to compete pathogens. Researchers have shown an increased interest in bacteriocins as a possible alternative to antibiotics. As mentioned earlier, our target in this study was to obtain an active bacteriocin in order to use it in a skin pharmaceutical formula. In preliminary tests, *Lactobacillus acidophilus HT1* showed an ability to produce an effective bacteriocin against some common skin pathogens in particular, *Pseudomonas aeruginosa*, *Klebsiella* sp and *Staphylococcus aureus* (data not shown). Therefore, this isolate was selected to be used to produce the bacteriocin that can be applied in a cream formula. The optimized cultural parameters that required for elevating bacteriocin production from *Lactobacillus acidophilus HT1* such as media (carbon and nitrogen sources), inoculum size, pH, temperature, and the incubation time were investigated. Different media were used in order to select the best one that can support the maximum production of bacteriocin. Based on the results presented in Figure 1A, the maximum production of bacteriocin was found when *L. acidophilus HT1* was grown in the Modified NB in which bacteriocin activity and biomass were 640AU/ml and 12.6 mg/ml respectively.
Then, the next step was to manipulate with media contents such as carbon source and nitrogen source. For this purpose, different carbon sources were used. Based on the results presented in Figure 1 B, the highest bacteriocin activity of 640 AU/mL was achieved when glucose was used as carbon source in which biomass was 12.6 mg/ml. In addition, results showed that glucose concentrations 20, 25, and 30 g/L gave the highest bacteriocin production with 640 AU/mL, however the production of biomass was varied ranging from 12.6 to 5.8 mg/ml (Figure 1D). Accordingly, the product yield factor on biomass $Y_{P/X}$, which relates to the amount of bacteriocin formed to the amount of biomass produced, was 0.05, 0.07, 0.11 in the cultures contained 20, 25 and 30 g/L glucose respectively. Therefore, the 30 g/L was chosen as the best concentration of glucose to be used in further experiments. Basically, modified nutrient medium contain peptone and yeast extract which were subjected to an optimization strategy in order to choose one source that support both growth and bacteriocin production by *L. acidophilus* HT1. The procedure was based mainly on the removal experiment optimization approach as follow: first, each nitrogen source was investigated separately at 7 g/L then half and equally for the two-nitrogen sources amount. The presence of both nitrogen sources (yeast extract and peptone) was necessary to supported bacteriocin production. However, maximum bacteriocin production of 640 AU/ml was observed in control medium. The results showed that bacteriocin production was suppressed in media 1 and 2 as shown in Figure 1C, the best inoculums size for the maximum bacteriocin production was 2% as shown in Figure 2A. Moreover, results showed that the maximum production of bacteriocin was obtained at 37°C and pH 6 (Figure 2B, 2C). Furthermore, maximum production of bacteriocin was observed after 24hrs of incubation with an activity of 640 AU/ml.

![Figure 1](image1.png)

**Figure 1.** Optimization of culture conditions for bacteriocin production by *L. acidophilus* HT1: best medium (A), carbon source (B), nitrogen source (C), carbon source concentration (D)

1385
Next, bacteriocin produced by *L. acidophilus* HT was precipitated from the culture supernatant by saturation with different concentrations of ammonium sulfate ranging from 20 to 90%, followed by dialysis to remove salts and impurities. Based on the results maximum bacteriocin precipitation was obtained at 70% saturation level. The bacteriocin activity was 1280 AU/ml with specific activity of 4266.6 AU/mg. The precipitated bacteriocin was then loaded in sephadex G-50. The antimicrobial assay was performed for each fraction using *P. aeruginosa* as indicator strain by agar well assay., two separated peaks were obtained in the separation profile. The bacteriocin activity was found in the fractions 31 to 36 (Figure 3). The active fractions were collected and concentrated by sucrose to obtain the 5 ml, the activity as well as specific activity of the partial purified bacteriocin was calculated as demonstrated in the purification (Table 2).
Figure 3. Purification of bacteriocin produced by L. acidophilus HT1 by Sephadex G-50 column (3 × 20 cm). Column was equilibrated and eluted with sodium phosphate buffer, pH 7 at a flow rate of 0.6 ml/min.

Table 2. Summary of purification of bacteriocin from crude culture filtrate of L. acidophilus HT1

| Purification steps                                      | Volume ml | Activity (U/ml) | Protein concentration mg/ml | Total activity U | Specific activity U/mg | Yield % | Fold purification |
|--------------------------------------------------------|-----------|-----------------|----------------------------|------------------|------------------------|---------|------------------|
| Crud extract                                           | 100       | 640             | 0.5                        | 64000            | 1280                   | 100     | 1                |
| Ammonium salt precipitation 70%                        | 15        | 1280            | 0.3                        | 19200            | 4266.6                 | 30      | 3.33             |
| Gel filtration sephadex G 50 after concentrated by sucrose | 5         | 2560            | 0.2                        | 12800            | 12800                  | 20      | 10               |

Next, the main characters of the purified bacteriocin were investigated. As can be seen in (Figure 4A), bacteriocin activity was reduced when treated with trypsin. The results showed that bacteriocin activity was decreased to 50% (1280 AU/ml) after 30 min of incubation and it was completely lost after 90 mins confirming the protein nature of bacteriocin. Thermal stability of bacteriocin is an important criterion that can help to determine whether the bacteriocin is belong to the class of heat-labile or heat –stable protein (11). As can be seen in Figure 4B, the activity of bacteriocin was kept stable after 10 min at 20, 30, 40 °C as no effect was observed on its antimicrobial activity. However, approximately 50% of the bacteriocin activity was lost after exposure to 50°C for 10min and further decreased to 160 AU/ml at 60°C and decreased gradually at 70°C and to reach to 20 AU/ml at 80 °C. From these results, it can be concluded that the bacteriocin is heat –labile. In addition, results revealed that bacteriocin activity showed stability at pH 6 and 7 in which the bacteriocin kept its activity of 2560 AU/ml for 30 min. However, bacteriocin activity was decreased to approximately 50% (1280 AU/ml) at pH 8, whereas, no activity was observed at pH 4 and 9 as shown in Figure 5. On the other hand, the mode of action of the partially purified bacteriocin was studied using P. aeruginosa as an indicator strain. According to results, a rapid decline in the number of viable cells Figure (6 A) and optical density Figure (6 B) in the tube which contained P. aeruginosa culture with bacteriocin was observed. The number of cells in this tube was decreased to approximately zero within 2 hrs. Whereas, no effect was seen on the growth of P. aeruginosa in the control tube. These results suggest that the bacteriocin has a bactericidal effect rather than bacteriostatic. Bacteriocins may possess a bactericidal or bacteriostatic mode of action on sensitive cells, this distinction being greatly influenced by several factors such as bacteriocin dose and degree of purification, physiological state of the indicator cells and experimental conditions (3). The next step was applied the bacteriocin in a suitable pharmaceutical formula.
Bacteriocins are antibacterial proteins produced by bacteria that kill or inhibit the growth of other bacteria (4). In this study, because the bacteriocin produced from *L. acidophilus HT1* is protein and soluble in water, therefore the formula must contain materials maintain this chemical structure with its activity. Thus, bacteriocin was prepared as a cream and examined *in vitro* and *in vivo*. In *in vitro* experiment, the antibacterial activity of cream formula containing bacteriocin was investigated against *P. aeruginosa* using well diffusion assay. According to results, a significant inhibition zones were observed around wells contained the bacteriocin-containing cream. Inhibition of *P. aeruginosa* growth was certainly demonstrated the efficiency of the formula through several points included; activity of bacteriocin and its releasing throughout the formula to the external environment (tested media). The results confirmed the absence of trapping or interaction among bacteriocin and any component of the formula that may counteract bacteriocin ability to inhibit tested bacteria. In addition, the bacteriocin-containing formula was tested *in vivo* with ultimate aim of application for the improvement of antimicrobial effect for the removal of pathogenic bacteria. As can be seen in Figures 7, 8 and 10, the infected wounds were varied during the period of experiment from severe inflammation that may be sometime became purulent especially for *S. aureus* group to mild inflammation and healing. In addition, the results showed that, all usable pathogenic bacteria were susceptible to the bacteriocin in particular, *Klebsiella* sp. which was more susceptible than other indicator bacteria. Furthermore, all groups of experiment exhibited a significant prophylactic effect (treatment was begun at the onset time of infection) of bacteriocin against pathogenic bacteria. Moreover, treatment at the onset time was more effective and consequently the time of complete healing was decreased. In addition, the formula showed an improvement in the efficiency based on its capability to support bacteriocin which acts as active ingredient to reach different parts of skin and prevent the dominant of severe infection.

![Figure 4](image-url)  
*Figure 4. Effect if trypsin (A) and temperature (B) on bacteriocin produced by *Lactobacillus acidophilus* HT 1*
Figure 5. pH stability of bacteriocin from *Lactobacillus acidophilus* HT 1 after exposed to different pH for 30 min.

Figure 6. Mode of action of partially purified bacteriocin produced by *L. acidophilus* HT1 against *P. aeruginosa*. Viable cell counts (CFU/ml) in the absence or presence of partial purified bacteriocin (A). Optical density at 600 nm in the absence or presence of partial purified bacteriocin (B).
| Type of formula                                      | 3 days | 5 days | 7 days |
|-----------------------------------------------------|--------|--------|--------|
| Complete formula with bacteriocin against *S. aureus* | ![Image] | ![Image] | ![Image] |
| Complete formula components only                     | ![Image] | ![Image] | ![Image] |
| Treatment with complete formula at the onset of infection | ![Image] | ![Image] | ![Image] |
| Control                                             | ![Image] | ![Image] | ![Image] |

Figure 7. *In vivo* experiment for applying bacteriocin produced by *L. acidophilus HTI* formula to treat a group of rabbits infected with *Staphylococcus aureus*. 
Figure 8. *In vivo* experiment for applying bacteriocin produced by *L. acidophilus HT1* formula to treat a group of rabbits infected with *Klebsiella sp.*
| Type of formula                  | After (3 days) | (5 days) |
|---------------------------------|---------------|---------|
| Complete formula with bacteriocin against *P. aeruginosa* | ![Image](image1) | ![Image](image2) |
| Complete formula components only | ![Image](image3) | ![Image](image4) |
| Treatment with complete formula at the onset of infection | ![Image](image5) | ![Image](image6) |
| Control                         | ![Image](image7) | ![Image](image8) |

**Figure 9.** *In vivo* experiment for applying bacteriocin produced by *L. acidophilus HT1* formula to treat a group of rabbits infected with *P. aeruginosa*

**REFERENCES**

1. AL-Gbouri and A. G. Hamzah, 2018. Evaluation pf phyllanthus emblica extracts as antibacterial and antibiofilm against biofilm formation bacteria. Iraq J Agri Sci. 49(1) 22-40
2. Abd, F.N. and K. Luti, 2017. An Exploitation of Interspecies Interaction for Promoting Bacteriocin Production by Local Isolate of *Bacillus.sp* M.Sc. Thesis. Department of Biotechnology, College of Science, University of Baghdad. 60:( 3) 494-508
3. Cintas, L. M.; C. Herranz ; P. E. Hernández; M. P. Casaus and L. F. Nes, 2001. Review: Bacteriocins of lactic acid bacteria. Food Sci. Tech. Int; 7: 281-305
4. Cleeeland, J.; T. J. Montville; I.F. Nes and M.L. Chikindas, 2001. Bacteriocins : Safe, natural antimicrobial for food preservation International J Food Microbiol; 71: 1-20
5. Chin, H. S.; J. S. Shim; J. M. Kim; R. Yang and S. S. Yoon, 2001. Detection and antibacterial activity of a bacteriocin produced by Lactobacillus plantarum. Food Sci. and Biotechnol., 10(5): 461-467.

6. Charles, P.; V. Devanathan; P. Anbu; M. N. Ponnuuswamy ; P. T.Kalaichelvan and B. K. Hur, 2008. Purification, characterization and crystallization of an extracellular alkaline protease from Aspergillus nidulans HA-10. J. of bas. Microbial., 48(5): 347-352.

7. Cinque, B.; C Torre; E. Melchiorre; G. Marchesani; G. Zoccali; G;Palumbo, P.; Marzio, L. D.; Masci, A.; Mosca, L.; Mastromarino, P.; Giuliani, M. and M. G. Cifone,. 2011. Use of probiotics for dermal applications. In: Probiotics, Microbiology Monographs. Lione, M.-T., Ed., Springer Verlag, Berlin, Heidelberg. 10(9): 460-468.

8. Dyae, N. and K. Luti, 2019. Classical and statistical optimization by response surface methodology for enhancing biomass and bacteriocin production by Lactobacillus Plantarum. Iraqi J of Sci, ; 60:(3) 494-508.

9. Eid, R ; J.E Jakee ; A. Rashidy; H. Asfour; S. Omara ; M.M.Kandil; Z.Mahmood; J. Hahne and A.A. Seida. 2016. Potential antimicrobial activities of probiotic Lactobacillus strains isolated from raw milk. Probiot. Health; 4: 138.

10. Fuller, R. 1989. Probiotic in man and animals: A review. J. Appl. Bacteriol; 66: 365–378.

11. Heng, N.C.K.; P.A. Wescombe ; J.P. Burton ; R.W. Jack and J.R. Tagg, 2007. The diversity of bacteriocins in Gram-positive bacteria. In: Bacteriocins: Ecology and evolution. riley MA and Chavan M. Springer, Berlin; 7: 45-92.

12. Hammami, I.; B. Jaouadi ; A. Ben Bacha ; A. Rebai ; S. Bejar ; X. Nesme and R. Ali, 2012. Bacillus subtilis bacteriocin Bac 14B with a broad inhibitory spectrum: purification, amino acid sequence analysis, and physicochemical characterization. Biotechnol. and Bio,Eng, 17: 41-49.

13. Harder, J.; J. Bartels; E. Christophers and JM. Schroder ,1997. A peptide antibiotic from human skin. Nature; 387:861.

14. Kruger, N.J. 2002. The Bradford Method of Protein Quantification. In J.W. Walker (ed.). The Protein Protocols Handbook, 2nd ed. Humana Press Inc.; Totowa, New Jercy. 9: 15-21.

15. Khaleel, M. M. and A. A. Thaer, 2017. Using probiotic and inulin to prolong fermented dairy products shelf. Iraq J Agri Sci. 48 (2): 608-617.

16. Mahdi, L. H. 2017. Immumodulatory of Bifidobacterium breve and inhibitory effect of bifidobrevicin LHM on Streptococcus agalactiae and ITSβ- hemolysin. Iraq J Agri Sci. 48: (Special Issue): 651-671.

17. Mishra, A.; S. Saklani ; L. Milella and P. Tiwari, 2014. Formulation and evaluation of herbal antioxidant face cream of Nardostachys jatamansi collected from Indian Himalayan Region. Asian Pac J Trop Biomed; 4:679-82.

18. Mayr-Harting, A.; A.J. Hedges and C.W. Berkeley, 1972. Methods for studying bacteriocins. Methods Microbiol; 7: 315–412.

19. Shih-Chun, Y.; L. Chih-Hung; S. Calvin and F. Jia-You, 2014. Antibacterial activities of bacteriocins: application in foods and pharmaceuticals; 5: 241-7.

20. Sirtori, L. R.; A. D. Motta and A. Brandelli, 2008. Mode of action of antimicrobial peptide P45 on Listeria monocytogenes. Journal of Basic Microbiology, 48(5):393-400.

21. Todorov S. D. and L. M. T. Dicks, 2004. Influence of Growth conditions on the production of a bacteriocin by Lactococcus lactis subp, lactis ST 34BR, a strain isolated from barley beer. Journal of Basic Microbiology; 44:305-316.

22. Yamato, M.; K. Ozaki and F. Ota, 2003. Partial purification and characterization of the bacteriocin produced by Lactobacillus acidophilus YIT 0154. Microbiol. Resea.,158 (2):169-172.

23. Zacharof M. P. and R. W. Lovittb, 2012. Bacteriocins Produced by Lactic Acid Bacteria, A Review Article, Bangkok, Thailand. April 7-8.